<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266239</url>
  </required_header>
  <id_info>
    <org_study_id>J-REVERSE</org_study_id>
    <nct_id>NCT01266239</nct_id>
  </id_info>
  <brief_title>Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion</brief_title>
  <acronym>J-REVERSE</acronym>
  <official_title>Japanese Registry Study in Comparison Between Everolimus-eluting Stent and Sirolimus-eluting Stent for the Bifurcation Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Yukuhashi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shin Yukuhashi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In study-1, the purpose of this study is to compare the long-term outcome of provisional
      stenting between EES and SES deployment. In study-2, it is to prove the following hypothesis
      &quot; Asymmetrical expansion in the bifurcation lesion leads to frequent inhomogeneous intimal
      growth on the strut and thrombus attachment.&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kissing balloon inflation brings asymmetrical expansion which may lead to a risk of
      disturbance of endothelialization. We will investigate the following issues.

        1. Impact of asymmetric expansion induced by kissing balloon technique on mid and long term
           results

        2. Difference between SES and EES

        3. Impact of abnormal OCT findings on long-term clinical outcome (3yr)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death, myocardila infarction, target lesion revascularization, target vessel revascularization, and stent thrombosis are monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abnormal intimal coverage</measure>
    <time_frame>9 months</time_frame>
    <description>Optical coherence tomography (OCT) is planned at the 9-month follow-up period. Unevenness of intimal growth, number of uncovered struts, and frequency of thrombus attachment are evaluated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>SES-KB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SES-NK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SES is deployed in the MV without kissing balloon inflation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EES-KB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EES-NK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EES is deployed in the MV without kissing balloon inflation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>kissing balloon inflation</intervention_name>
    <description>Kissing balloon inflation following the MV stenting</description>
    <arm_group_label>SES-KB</arm_group_label>
    <arm_group_label>SES-NK</arm_group_label>
    <arm_group_label>EES-KB</arm_group_label>
    <arm_group_label>EES-NK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EES vs. SES</intervention_name>
    <description>Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.</description>
    <arm_group_label>SES-KB</arm_group_label>
    <arm_group_label>SES-NK</arm_group_label>
    <arm_group_label>EES-KB</arm_group_label>
    <arm_group_label>EES-NK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Coronary bifurcation lesion which stenotic lesion exists in the MV and / or in the
             side branch (SB).

          2. The lesion is appropriate for the provisional MV stenting.

          3. The reference diameter is more than 2.5mm in the MV and more than 2.0mm in the SB.

        Exclusion Criteria:

          1. Left main coronary bifurcation

          2. Acute myocardial infarction and unstable angina which culprit vessel contains obvious
             thrombus

          3. Left ventricular ejection fraction &lt; 30%

          4. Shock state

          5. Inappropriate candidate for the dual antiplatelet therapy, administration of contrast
             medium and radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshinobu Murasato, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Yukuhashi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshihisa Kinoshita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toyohashi Heart Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoshinobu Murasato, MD, PhD</last_name>
    <phone>+81-930-24-8899</phone>
    <email>murasato@shinyukuhashihospital.or.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoshihisa Kinoshita, MD</last_name>
    <phone>+81-532-37-3377</phone>
    <email>Ykinoshita@heart-center.or.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiro Shinke, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Toshiro Shinke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiromasa Otake, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo Medical University</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenichi Fujii, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kenichi Fujii, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toyohashi Heart Center</name>
      <address>
        <city>Toyohashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihisa Kinoshita, MD</last_name>
      <phone>+81-532-37-3377</phone>
      <email>Ykinoshita@heart-center.or.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshihisa Kinoshita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Yamawaki, MD, PhD</last_name>
      <email>m_yamawaki@tobu.saiseikai.or.jp</email>
    </contact>
    <investigator>
      <last_name>Masahiro Yamawaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Yukuhashi hospital</name>
      <address>
        <city>Yukuhashi</city>
        <zip>824-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshinobu Murasato, MD, PhD</last_name>
      <phone>+81-930-24-8899</phone>
      <email>murasato@shinyukuhashihospital.or.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshinobu Murasato, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yoshinobu Murasato</name_title>
    <organization>New Yukuhashi Hospital</organization>
  </responsible_party>
  <keyword>Bifurcation lesion, drug-eluting stent, symmetric expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

